Nektar Is Still a Favorite

Nektar in the NEWS
The FDA's Anesthetic and Analgesic Advisory Committee (AADPAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) unanimously voted no regarding the approval of Nektar Pharmaceuticals’ (NKTR) New Drug Application (NDA) for its opioid product oxycodegol (formerly NKTR-181).

In a short This content is for paid subscribers.

Please click here to subscribe or here to log in.